Brief: Biorestorative Completes Patient Enrollment In Landmark Phase 2 Trial Of Brtx-100 For Chronic Lumbar Disc Disease
10/02/2026 15:29
Feb 10 (Reuters) - BioRestorative Therapies Inc BRTX.O: BIORESTORATIVE COMPLETES PATIENT ENROLLMENT IN LANDMARK PHASE 2 TRIAL OF BRTX-100 FOR CHRONIC LUMBAR DISC DISEASE Source text: ID:nGNX4fSDrZ Further company coverage: BRTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biorestorative Therapies
See all newsBioRestorative Therapies Inc expected to post a loss of $2.50 a share - Earnings Preview
BioRestorative Therapies Inc expected to post a loss of $2.50 a share - Earnings Preview
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM